Clinical Trial Update: Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating the combination of ibrutinib and nivolumab for relapsed or refractory classical Hodgkin lymphoma, sponsored by the Ohio State Un…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma

Drugs mentioned

• IMBRUVICA (IBRUTINIB)
• OPDIVO (nivolumab)

Snippet

Sponsor: Ohio State University Comprehensive Cancer Center | Conditions: Classical Hodgkin Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING